Poor
Not Aligned
Patient Risk:
Moderate
Summary
Multiple administration details are incorrect or unsupported (notably infusion duration and dilution), and several safety/monitoring and interaction/autoimmune guidance claims are not supported by the provided label excerpts.
Category Scores
Accurate Statements
Yervoy (ipilimumab) is a monoclonal antibody.
Supported by label description/mechanism.
The recommended Yervoy regimen is for a maximum of 4 doses.
Supported for unresectable or metastatic melanoma in Table 1.
For unresectable or metastatic melanoma, recommended dosage is 3 mg/kg every 3 weeks (maximum 4 doses).
Supported for dose amount and interval; infusion duration claim is where it diverges.
Yervoy dosage should be calculated based on the patient's body weight.
Supported by PK section noting body-weight–based dosing.
Serious side effects of Yervoy include colitis, pneumonitis, and endocrinopathy.
Supported as immune-mediated adverse reactions with dosing modifications in Table 3.
Treatment with Yervoy should be discontinued if these side effects occur.
Partially supported: Table 3 provides severity-dependent withhold vs permanently discontinue, not universal discontinuation.
Unsupported Statements
Yervoy should be diluted with 0.9% sodium chloride injection before administration.
No dilution instructions are present in the provided label excerpts (2.4).
Common side effects of Yervoy include fatigue, rash, itching, and diarrhea.
No available provided label section lists these as common side effects.
Patients should be closely monitored for signs of these Yervoy side effects.
Provided excerpts do not explicitly state 'closely monitored' for colitis/pneumonitis/endocrinopathy.
Yervoy dosage may need to be adjusted in special populations, such as patients with renal impairment or those taking certain medications.
Partially supported at most: renal impairment effect on clearance is described as not clinically important (for GFR ≥15), and no provided excerpt supports dose adjustment guidance for drug-taking scenarios.
Patients with a history of autoimmune disorders may require dose adjustments of Yervoy.
No provided label excerpt discusses autoimmune history requiring dose adjustments.
Patients with renal impairment may require dose adjustments to prevent accumulation of Yervoy.
No provided excerpt supports accumulation-prevention via dose adjustment; renal impairment is described as having no clinically important effect on clearance in the specified range.
Patients with severe renal impairment required a 50% dose reduction of Yervoy in the cited study.
No provided label excerpt describes a 50% dose reduction for severe renal impairment.
Yervoy may interact with other medications, including immunosuppressants and anticoagulants.
No provided excerpt supports interactions with immunosuppressants or anticoagulants; provided interaction discussion focuses on nivolumab/chemotherapy.
Patients should inform their healthcare provider of all medications they are taking to avoid potential interactions.
The provided patient counseling excerpt does not include specific interaction counseling.
Contradictions
Low
AI Statement
The Yervoy infusion should be given over a period of 90 minutes.
Label Reference
2.2 Recommended Dosage: 'Administer YERVOY as a 30-minute intravenous infusion.'
Important Omissions
Dose administration instruction that YERVOY is administered as a 30-minute intravenous infusion (rather than 90 minutes).
Importance:
High
General adverse reaction management guidance (withhold vs permanently discontinue based on Grade/severity) rather than implying discontinuation based solely on occurrence.
Importance:
Moderate
Explicit statement that no dose reduction is recommended and that management is grade-based (withhold for Grade 3 immune-mediated adverse reactions; permanently discontinue for Grade 4 life-threatening).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
An administration-time contradiction (90 vs 30 minutes) and an unsupported dilution instruction could lead to incorrect administration. Additional unsupported counseling/monitoring and interaction claims further increase risk of mismanagement relative to the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Multiple administration and safety-detail inaccuracies/unsupported claims, especially infusion duration and dilution instruction.
Suggested Improvement
Remove or correct the infusion duration to the labeled 30-minute IV infusion and avoid adding dilution instructions not present in the provided label excerpt; ensure adverse reaction management wording matches the label’s grade-based withhold vs permanently discontinue guidance.